| Hayes Evolving Evidence Review (OPRA, 2023; updated 2025) | Found limited/low-quality evidence and no/unclear support for OPRA in transfemoral amputations; high revision and infection rates reported; 2024–25 updates did not change level of support. |
| ECRI clinical assessment (2022) | Concluded evidence inconclusive for OPRA; low-quality studies report mobility/QOL improvements but frequent serious complications (infections, implant loosening) leaving uncertain risk-benefit balance. |
| Sinclair et al. (2022) — POP study (n=10) | Prospective FDA IDE single-center study: safety concerns including device removals, infection, periprosthetic fracture; small sample and two device removals during follow-up. |
| Hagberg et al. (2022) — OPRA 10-year cohort (n=51) | Patient-reported outcomes improved at 10 years, but revision-free survival at 10 years: implant revision 83% (CI 69%-91%), deep infection 65% (CI 49%-77%), mechanical complications 17% (CI 7%-29%); high mechanical complication incidence and notable implant removals. |
| Hagberg et al. analyses (mechanical complications rates) | Mechanical complications constituted most common serious adverse event (3.9 per 10 person-years); mechanical complications increased in later five years; deep infection incidence ~0.3 per 5 person-years. |
| Brånemark et al. (2019) / Hagberg et al. (2020) longer cohorts | Long-term cohorts report improved prosthetic use and mobility but frequent superficial and deep infections and numerous mechanical complications requiring hardware replacement; fixture survival maintained but adverse events substantial. |
| Toderita et al. (2024) & Ranaldi et al. (2023) | Small comparative and case-series data show some gait and Q-TFA score improvements after osseointegration, but studies are small, non-generalizable, and lack long-term outcomes. |
| Klenow et al. (2024) — Genium MPK RCT | Randomized trial of Genium enhancements: stumble frequency reduced 85% (p=0.008); unilateral group showed reductions in residual limb and low back pain and ADL improvements; sample small and limitations noted. |
| Morgan et al. (2024) — early rehab MPK pilot RCT | Pilot RCT: MPK users had higher mobility and balance scores (PLSOM p=.01; ABC p=.01) and better return-to-normal-living scores; small sample but favored MPK in early rehab. |
| AHRQ Lower Limb Prostheses review (2018) | Identified 77 articles; evidence limited by small/nonrandomized studies and lack of long-term US data; insufficient/low evidence on many long-term outcomes. |
| Hayes Evolving Evidence Review (Powered MPAs, 2022; updates 2023–24) | Minimal support for powered microprocessor prosthetic ankles: small, low-quality, inconsistent studies; 2023–24 updates did not change conclusions. |
| Kim et al. (2021) randomized trial (BiOM) | Small RCT (n=12) found no significant differences between powered and unpowered prostheses on metabolic cost, activity, or perceived mobility; device issues and small sample limit conclusions. |
| Brannen et al. (2025) — powered hip prototype | Prototype passed ISO 15032:2000 strength tests and enabled level walking in three able-bodied subjects, but functional testing limited and design limitations noted; early-stage evidence. |
| Kannenberg et al. (2022) survey on PwrAF users | Cross-sectional survey (n=46 analyzed) reported improvements in pain and mobility among current powered ankle users after recall adjustment, but limitations include recall bias, small and male-only sample, and many former users reverted to passive feet. |